Ascendis Health Limited

Johannesburg Stock Exchange ASC.JO

Ascendis Health Limited Net Income Margin for the year ending June 30, 2024: 2.82%

Ascendis Health Limited Net Income Margin is 2.82% for the year ending June 30, 2024, a -42.43% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Ascendis Health Limited Net Income Margin for the year ending June 30, 2023 was 4.91%, a -82.97% change year over year.
Ascendis Health Limited Net Income Margin for the year ending June 30, 2022 was 28.80%, a 158.86% change year over year.
Ascendis Health Limited Net Income Margin for the year ending June 30, 2021 was -48.94%, a -240.47% change year over year.
Ascendis Health Limited Net Income Margin for the year ending June 30, 2020 was -14.37%, a 82.85% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Johannesburg Stock Exchange: ASC.JO

Ascendis Health Limited

CEO	Mr. A. Carl Neethling
IPO Date	Nov. 22, 2013
Location	South Africa
Headquarters	31 Georgian Crescent East
Employees	3,200
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Personal Care

Description

Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Hungary, Romania, and internationally. The company operates through Consumer Health, Pharma, and Medical segments. It offers body and skin products; and natural supplements, multi-vitamin and mineral supplements, micronutrient supplements, nutraceutical supplements, vitamins, minerals, and homeopathic and herbal products under the Bettaway, Chela-Fer, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Nimue, Scitec, Solal, and Vitaforce brand names. The company also provides medical devices, and diagnostic laboratory equipment and consumables for operating theatres, ICUs, trauma units, maternity and general wards, radiology, pathology labs, research and science institutes, etc.; generic pharmaceutical products, antineoplastic agents, antivirals, aromatase inhibitors, anti-infectives; and products for the nervous system, cardiovascular system, dermatological products, and antimalarials, as well as other therapeutic products under the Pharmachem, Reuterina, Sinucon, Clonam, Phlexy, Surgical Innovations, RCA, and The Scientific Group brands. In addition, it exports its products. The company serves pharmacies, retailers, beauticians, and doctors. Ascendis Health Limited was incorporated in 2008 and is based in Johannesburg, South Africa.

Key trends

Past 5 years